We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alkemy Capital Investments Plc | LSE:ALK | London | Ordinary Share | GB00BMD6C023 | ORD GBP0.02 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.00 | -5.13% | 92.50 | 90.00 | 95.00 | 97.50 | 92.50 | 97.50 | 54,098 | 09:45:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Offices-holdng Companies,nec | 0 | -2.65M | -0.3239 | -2.86 | 7.55M |
TIDMALK TIDMB
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 16 March 2022.
The Annual General Meeting transacted the following business:
-- Adoption of the annual report 2021 and discharge of the Board of Directors and Board of Management -- No declaration of ordinary dividend in accordance with the approved annual report for 2021 -- Adoption of the remuneration report for 2021 -- Adoption of the remuneration to the Board of Directors for the present year -- Re-election of Anders Hedegaard as the Chairman of the Board of Directors -- Re-election of Lene Skole as the Vice Chairman of the Board of Directors -- Re-election of Gitte Aabo, Lars Holmqvist, Bertil Lindmark and Jakob Riis as well as new election of Alan Main to the Board of Directors -- Re-appointment of PwC Statsautoriseret Revisionspartnerselskab as the company's auditor -- Adoption of the following proposals from the Board of Directors:
(a) Renewal of the Board's powers to increase the share capital (article 4a of the Articles of Association)
(b) Amendment of the denomination of shares
(c) Amendment of article 6.4 of the Articles of Association
(d) Authorisation to the chairman of the meeting
ALK-Abelló A/S
For further information please contact:
Anders Hedegaard, Chairman, tel. +45 4574 7576
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
-- FM_05_22UK_16032022 https://ml-eu.globenewswire.com/Resource/Download/19ec0e6e-5701-4b3d-95be-8de086a1b806
(END) Dow Jones Newswires
March 16, 2022 12:58 ET (16:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Alkemy Capital Investments Chart |
1 Month Alkemy Capital Investments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions